Palvella Therapeutics (PVLA) Other Operating Expenses (2013 - 2024)
Palvella Therapeutics (PVLA) posted quarterly Other Operating Expenses of $1.7 million for Q4 2024, up 111.2% year-over-year from $789773.1 in Q1 2024, and up 393.66% quarter-over-quarter from -$568000.0 in Q3 2024.
Palvella Therapeutics (PVLA) Other Operating Expenses (2013 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Other Operating Expenses for 3 consecutive years, with $1.7 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Other Operating Expenses rose 111.2% year-over-year to $1.7 million; the TTM figure through Sep 2025 stood at $1.7 million (up 110.79% YoY), while the FY2024 annual figure was $1.1 million, down 95.24% from the prior year.
- Other Operating Expenses rose to $1.7 million in Q4 2024 per PVLA's latest filing, from -$568000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $14.9 million in Q3 2023 and bottomed at -$14.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | -568,000.00 |
| Dec 31, 2023 | -14.89 Mn |
| Sep 30, 2023 | 14.89 Mn |
| Dec 31, 2013 | 7,912.00 |
| Sep 30, 2013 | 5,750.00 |